Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
A Phase I/II Study of Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen
Sponsor: National Cancer Institute (NCI)
This PHASE1/PHASE2 trial investigates Central Nervous System Lymphoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 10 recorded versions since 2005 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Oct 2021 — Oct 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Cincinnati, United States
- • Cleveland, United States
- • Columbus, United States
- • Portland, United States